Pancella Inc.
$400,000.00 CAD
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2019-2020
- Agreement period
- January 1, 2020 – January 31, 2022
- Reference
- nrc-cnrc:172-2019-2020-Q4-947179
Published purpose
panKiller is an extension of panCELLa's proprietary FailSafe. panKiller is covered by the same patent as FailSafe: TOOLS AND METHODS FOR USING CELL DIVISION LOCI TO CONTROL PROLIFERATION OF CELLS. The patent was filed globally in most industrialized nations. panKiller involves the integration of a two-step safety switch. The first step utilizes FailSafe while the next step will utilize a second safety switch, panKiller, in order to eliminate all the therapeutic cells once therapy is complete and the therapeutic cells are no longer required. panKiller will link a suicide gene (iCaspase9) to a gene essential for cell survival (EEF2) in human induced pluripotent stem cells. There are currently no two-step safety switches on the market.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.